CARVEDILOL PLUS NUCS TO PREVENT THE PROGRESSION OF ESOPHAGEAL VARICES IN VIROLOGICAL SUPPRESSED HBV-CIRRHOSIS PATIENTS: A RANDOMISED, OPEN-LABEL TRIAL

被引：0

作者：

Wang, Bingqiong ^{[1
]}

Zhou, Jialing ^{[1
]}

Wu, Xiaoning ^{[2
]}

Sun, Yameng ^{[2
]}

Li, Lei ^{[3
]}

Li, Ping ^{[4
]}

Li, Minghui ^{[5
]}

Jiang, Wei ^{[6
]}

Xu, Mingyi ^{[7
]}

Feng, Bo ^{[8
]}

Xu, Xiaoyuan ^{[9
]}

Cheng, Jilin ^{[10
]}

Xie, Wen ^{[11
]}

Han, Tao ^{[12
]}

Wang, Xiaozhong ^{[13
]}

Li, Hai ^{[14
]}

Piao, Hongxin ^{[15
]}

Zhao, Xinyu ^{[16
,17
,18
]}

Chen, Shuyan ^{[5
]}

Meng, Tongtong ^{[2
]}

Guan, Qiushuang ^{[1
]}

Meng, Fandong ^{[19
]}

Kong, Yuanyuan ^{[20
,21
]}

Ou, Xiaojuan ^{[2
]}

Jia, Jidong ^{[2
]}

You, Hong ^{[5
]}

机构：

[1] Capital Med Univ, Beijing Key Lab Translat Med Liver Cirrhosis, Natl Clin Res Ctr Digest Dis, Liver Res Ctr,Beijing Friendship Hosp, Beijing, Peoples R China

[2] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Liver Res Ctr, Beijing, Peoples R China

[3] Capital Med Univ, Beijing Youan Hosp, Dept Gastroenterol & Hepatol, Beijing, Peoples R China

[4] Tianjin Second Peoples Hosp, Dept Hepatol, Tianjin, Peoples R China

[5] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China

[6] Fudan Univ, Dept Gastroenterol, Zhongshan Hosp Xiamen, Xiamen 361015, Peoples R China

[7] Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol & Hepatol, Shanghai Gen Hosp, Shanghai, Peoples R China

[8] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[9] Peking Univ First Hosp, Beijing, Peoples R China

[10] Shanghai Publ Hlth Clin Ctr, Dept Gastroenterol, Shanghai, Peoples R China

[11] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Beijing, Peoples R China

[12] Tianjin Med Univ, Dept Hepatol, Tianjin Cent Hosp 3, Tianjin, Peoples R China

[13] Xinjiang Med Univ, Xinjiang Hosp Tradit Chinese Med, Affiliated Hosp 4, Urumqi, Xinjiang, Peoples R China

[14] Tianjin Xiqing Hosp, Dept Gastroenterol, Tianjin, Peoples R China

[15] Yanbian Univ, Dept Infect Dis, Affiliated Hosp, Yanji, Jilin, Peoples R China

[16] Natl Clin Res Ctr Digest Dis, Dept Clin Epidemiol, Beijing, Peoples R China

[17] Natl Clin Res Ctr Digest Dis, EBM Unit, Beijing, Peoples R China

[18] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[19] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol, Beijing, Peoples R China

[20] Capital Med Univ, Beijing Friendship Hosp, Beijing Clin Res Inst, Clin Epidemiol, Beijing, Peoples R China

[21] Capital Med Univ, Beijing Friendship Hosp, Beijing Clin Res Inst, EBM Unit, Beijing, Peoples R China

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

206

引用

页码：S217 / S218

页数：2

共 50 条

[21] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
Cunningham, David
Lang, Istvan
Marcuello, Eugenio
Lorusso, Vito
Ocvirk, Janja
Shin, Dong Bok
Jonker, Derek
Osborne, Stuart
Andre, Niko
Waterkamp, Daniel
Saunders, Mark P.
LANCET ONCOLOGY, 2013, 14 (11): : 1077 - 1085
[22] A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in advanced cancer patients undergoing chemotherapy
Kaasa, Stein
Solheim, Tora
Laird, Barry J. A.
Balstad, Trude
Stene, Guro Birgitte
Bye, Asta
Fallon, Marie T.
Fayers, Peter
Fearon, Ken
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[23] Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial
de Niet, Annikki
Jansen, Louis
Stelma, Femke
Willemse, Sophie B.
Kuiken, Sjoerd D.
Weijer, Sebastiaan
van Nieuwkerk, Carin M. J.
Zaaijer, Hans L.
Molenkamp, Richard
Takkenberg, R. Bart
Koot, Maarten
Verheij, Joanne
Beuers, Ulrich
Reesink, Hendrik W.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08): : 576 - 584
[24] Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Rummel, Mathias
Kaiser, Ulrich
Balser, Christina
Stauch, Martina
Brugger, Wolfram
Welslau, Manfred
Niederle, Norbert
Losem, Christoph
Boeck, Hans-Peter
Weidmann, Eckhart
von Gruenhagen, Ulrich
Mueller, Lothar
Sandherr, Michael
Hahn, Lars
Vereshchagina, Julia
Kauff, Frank
Blau, Wolfgang
Hinke, Axel
Barth, Juergen
LANCET ONCOLOGY, 2016, 17 (01): : 57 - 66
[25] Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Hillmen, Peter
Robak, Tadeusz
Janssens, Ann
Babu, K. Govind
Kloczko, Janusz
Grosicki, Sebastian
Doubek, Michael
Panagiotidis, Panagiotis
Kimby, Eva
Schuh, Anna
Pettitt, Andrew R.
Boyd, Thomas
Montillo, Marco
Gupta, Ira V.
Wright, Oliver
Dixon, Iestyn
Carey, Jodi L.
Chang, Chai-Ni
Lisby, Steen
McKeown, Astrid
Offner, Fritz
LANCET, 2015, 385 (9980): : 1873 - 1883
[26] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Heinemann, Volker
von Weikersthal, Ludwig Fischer
Decker, Thomas
Kiani, Alexander
Vehling-Kaiser, Ursula
Al-Batran, Salah-Eddin
Heintges, Tobias
Lerchenmueller, Christian
Kahl, Christoph
Seipelt, Gernot
Kullmann, Frank
Stauch, Martina
Scheithauer, Werner
Hielscher, Joerg
Scholz, Michael
Mueller, Sebastian
Link, Hartmut
Niederle, Norbert
Rost, Andreas
Hoeffkes, Heinz-Gert
Moehler, Markus
Lindig, Reinhard U.
Modest, Dominik P.
Rossius, Lisa
Kirchner, Thomas
Jung, Andreas
Stintzing, Sebastian
LANCET ONCOLOGY, 2014, 15 (10): : 1065 - 1075
[27] Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in patients with locally advanced resectable esophageal squamous carcinoma: An open-label, single arm phase 2 trial.
He, Wenwu
Peng, Lin
Bao, Yu
Xiao, Wenguang
Fang, Qiang
Leng, Xuefeng
Yan, Jiaxin
Mao, Tianqin
Shen, Xudong
Huang, Depei
Zhang, Hushan
She, Xueke
Han, Yongtao
CANCER RESEARCH, 2021, 81 (13)
[28] Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial
Bhargava, Anurag
Bhargava, Madhavi
Meher, Ajay
Benedetti, Andrea
Velayutham, Banurekha
Teja, G. Sai
Watson, Basilea
Barik, Ganesh
Pathak, Rajeev Ranjan
Prasad, Ranjit
Dayal, Rakesh
Madhukeshwar, Adarsh Kibballi
Chadha, Vineet
Pai, Madhukar
Joshi, Rajendra
Menzies, Dick
Swaminathan, Soumya
LANCET, 2023, 402 (10402): : 627 - 640
[29] Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Pal, Sumanta Kumar
Albiges, Laurence
Tomczak, Piotr
Suarez, Cristina
Voss, Martin H.
de Velasco, Guillermo
Chahoud, Jad
Mochalova, Anastasia
Procopio, Giuseppe
Mahammedi, Hakim
Zengerling, Friedemann
Kim, Chan
Osawa, Takahiro
Angel, Martin
Gupta, Suyasha
Khan, Omara
Bergthold, Guillaume
Liu, Bo
Kalaitzidou, Melania
Huseni, Mahrukh
Scheffold, Christian
Powles, Thomas
Choueiri, Toni K.
LANCET, 2023, 402 (10397): : 185 - 195
[30] Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial
Waked, Imam
Shiha, Gamal
Qaqish, Roula B.
Esmat, Gamal
Yosry, Ayman
Hassany, Mohamed
Soliman, Reham
Mohey, Mohammad A.
Allam, Naglaa
Zayed, Naglaa
Asselah, Tarik
Hall, Coleen
Redman, Rebecca
Mobashery, Niloufar
Doss, Wahid
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (01): : 36 - 44

← 1 2 3 4 5 →